Compare Stocks: RCAT, TSHA, and SLSR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RCAT Red Cat	$4.43 +1.4%	$7.17	$4.14 ▼ $18.78	$536.38M	1.51	6.45 million shs	5.45 million shs
SLSR Solaris Resources	$6.65 +1.1%	$7.54	$5.91 ▼ $11.48	$1.10B	1.45	146,753 shs	107,312 shs
TSHA Taysha Gene Therapies	$3.96 -1.2%	$5.02	$3.45 ▼ $7.30	$1.30B	1.19	4.84 million shs	2.59 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RCAT Red Cat	-4.59%	-10.82%	-37.03%	-42.73%	-56.26%
SLSR Solaris Resources	-7.06%	+0.77%	-14.55%	-14.10%	+18.13%
TSHA Taysha Gene Therapies	-2.67%	+7.51%	-22.29%	-27.36%	-18.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RCAT Red Cat	$4.43 +1.4%	$7.17	$4.14 ▼ $18.78	$536.38M	1.51	6.45 million shs	5.45 million shs
SLSR Solaris Resources	$6.65 +1.1%	$7.54	$5.91 ▼ $11.48	$1.10B	1.45	146,753 shs	107,312 shs
TSHA Taysha Gene Therapies	$3.96 -1.2%	$5.02	$3.45 ▼ $7.30	$1.30B	1.19	4.84 million shs	2.59 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RCAT Red Cat	-4.59%	-10.82%	-37.03%	-42.73%	-56.26%
SLSR Solaris Resources	-7.06%	+0.77%	-14.55%	-14.10%	+18.13%
TSHA Taysha Gene Therapies	-2.67%	+7.51%	-22.29%	-27.36%	-18.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
RCAT Red Cat	2.70	Moderate Buy	$16.29	267.62% Upside
SLSR Solaris Resources	3.00	Buy	$18.00	170.68% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	222.46% Upside

Current Analyst Ratings Breakdown

Latest RCAT, TSHA, and SLSR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	RCAT Red Cat	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$9.00 ➝ $6.00
10/20/2026	RCAT Red Cat	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$15.00
10/15/2026	RCAT Red Cat	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/12/2026	RCAT Red Cat	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
9/21/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/17/2026	RCAT Red Cat	Northland Securities Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$13.00
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
9/2/2026	RCAT Red Cat	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$9.00
9/2/2026	RCAT Red Cat	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$9.00
8/31/2026	RCAT Red Cat	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$15.00
8/7/2026	RCAT Red Cat	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$20.00 ➝ $15.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
RCAT Red Cat	$40.73M	13.35	N/A	N/A	$2.06 per share	2.15
SLSR Solaris Resources	N/A	N/A	N/A	N/A	($0.29) per share	N/A
TSHA Taysha Gene Therapies	$9.77M	132.07	N/A	N/A	$0.90 per share	4.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
RCAT Red Cat	-$72.07M	-$0.81	N/A	N/A	N/A	-136.26%	-32.25%	-28.48%	N/A
SLSR Solaris Resources	-$42.23M	N/A	N/A	N/A	N/A	N/A	N/A	-43.67%	N/A
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest RCAT, TSHA, and SLSR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	TSHA Taysha Gene Therapies	-$0.1286	N/A	N/A	N/A	$0.76 million	N/A
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/6/2026	Q2 2026	RCAT Red Cat	-$0.21	-$0.26	-$0.05	-$0.26	$22.65 million	$20.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
RCAT Red Cat	N/A	N/A	N/A	N/A	N/A
SLSR Solaris Resources	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
RCAT Red Cat	N/A	14.86	11.89
SLSR Solaris Resources	N/A	8.42	8.39
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
RCAT Red Cat	37.97%
SLSR Solaris Resources	N/A
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
RCAT Red Cat	12.50%
SLSR Solaris Resources	N/A
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
RCAT Red Cat	244	122.74 million	107.40 million	Optionable
SLSR Solaris Resources	84	167.11 million	N/A	N/A
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

RCAT, TSHA, and SLSR Headlines

Recent News About These Companies

Financial Survey: Taysha Gene Therapies (NASDAQ:TSHA) versus ADMA Biologics (NASDAQ:ADMA)

October 20 at 4:15 AM | americanbankingnews.com

Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?

October 19, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Jumps 6.4% - Should You Buy?

October 15, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 52-Week Low - Time to Sell?

October 14, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5% - What's Next?

October 13, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value

October 9, 2026 | finance.yahoo.com

Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?

October 9, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Average Target Price of $12.77 According to Brokerages

October 7, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant under Nasdaq Listing Rule 5635(4)

October 6, 2026 | marketscreener.comM

Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 5.4% - Should You Sell?

October 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 4, 2026 | biospace.comB

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

October 1, 2026 | globenewswire.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened

September 28, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RCAT, TSHA, and SLSR Company Descriptions

Red Cat NASDAQ:RCAT

$4.43 +0.06 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$4.41 -0.02 (-0.45%)

As of 07:59 PM Eastern

Red Cat Holdings, Inc. engages in the provision of various products, services, and solutions to the drone industry. The company operates through two segments: Enterprise and Consumer. It built infrastructure to manages drone fleets and fly, and provide services remotely, navigate confined industrial interior spaces and dangerous military environment. Red Cat Holdings, Inc. is based in San Juan, Puerto Rico.

Solaris Resources NYSEAMERICAN:SLSR

$6.65 +0.07 (+1.06%)

Closing price 04:10 PM Eastern

Extended Trading

$6.67 +0.02 (+0.30%)

As of 07:55 PM Eastern

Solaris Resources Inc. engages in exploration of mineral properties. It focuses on exploring copper, molybdenum, gold, lead, zinc, and silver. The company's flagship project is the 100% owned Warintza Copper and Gold Project comprising nine metallic mineral concessions, which covers an area of 268 km2 located in Ecuador. It holds interest in Capricho and Paco Orco projects located in Peru; Ricardo and Tamarugo property in Chile; and La Verde property in Mexico. The company was formerly known as Solaris Copper Inc. and changed its name to Solaris Resources Inc. in December 2019. Solaris Resources Inc. was incorporated in 2018 and is based in Vancouver, Canada.

Taysha Gene Therapies NASDAQ:TSHA

$3.96 -0.05 (-1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 -0.08 (-1.92%)

As of 07:30 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCAT, TSHA, and SLSR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCAT, TSHA, and SLSR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCAT, TSHA, and SLSR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCAT, TSHA, and SLSR Company Descriptions

Red Cat NASDAQ:RCAT

Solaris Resources NYSEAMERICAN:SLSR

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCAT, TSHA, and SLSR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCAT, TSHA, and SLSR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCAT, TSHA, and SLSR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCAT, TSHA, and SLSR Company Descriptions

Red Cat NASDAQ:RCAT

Solaris Resources NYSEAMERICAN:SLSR

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools